Mixed Results for a Cancer "Cure"

Entremed's stock soared on hopes for its experimental drug Endostatin, but human trials are showing that it is no silver bullet

By Catherine Arnst

To continue reading this article you must be a Bloomberg Professional Service Subscriber.